Pharmacy Billing Services / 340B + DIR Reconciliation

Split the claim before the discount stacks, then reconcile net against point-of-sale pricing.

Here is the short answer. A specialty pharmacy protects its 340B margin by tagging every dispense as eligible or non-eligible at the point of adjudication, not in a month-end true-up. That single split prevents the duplicate discount HRSA prohibits, and it is the only clean baseline for reconciling the net revenue that shifted when CMS moved Part D DIR fees to the point of sale on January 1, 2024. Get the split right and the reconciliation is arithmetic. Get it wrong and you are choosing between a HRSA audit finding and a payer chargeback.

2claim streams, 1 NDC

SCC 20340B flag on Medicaid

Jan 2024DIR at point of sale

NADACFFS cost basis

The comparison matrix

One drug, two economic identities. The matrix is where you keep them straight.

Same NDC, same shelf, same patient sometimes. What changes is the acquisition price, the discount that is legally allowed to touch it, and how the claim has to be flagged. Read this matrix row by row before you build a single edit rule.

Reconciliation dimensionWhat you are comparing

340B-Eligible DispenseCovered entity patient

Non-340B DispenseCash / commercial / carve-out

Acquisition costIngredient basis

Purchased at or below the HRSA 340B ceiling price (the AMP minus URA calculation). This is the discount you are protecting.ceiling price

Purchased at WAC or GPO contract price. No statutory discount. Standard wholesale economics apply.WAC / GPO

Duplicate-discount riskThe audit trap

High. A 340B unit billed to Medicaid can trigger a manufacturer rebate on an already-discounted drug, which the statute forbids. Managed by the carve-in / carve-out decision and the HRSA Medicaid Exclusion File.prohibited stacking

None on the 340B axis. The drug never received a covered-entity discount, so the Medicaid rebate flows normally.rebate eligible

Claim flag requiredNCPDP fields

For Medicaid FFS carve-in, submit Submission Clarification Code 20 and the entity's 340B BIN/PCN routing so the state suppresses the rebate request.SCC 20

Standard adjudication. No 340B indicator. Do not let a non-eligible unit carry the 340B flag, that is a false positive the state will claw back.no indicator

Reimbursement basisWhat the payer pays

Medicaid FFS increasingly pays NADAC-based ingredient cost plus a professional dispensing fee, independent of your low 340B acquisition. The spread is the program's intended benefit.NADAC + PDF

Commercial and Part D pay a negotiated network rate; Medicaid FFS pays NADAC or the pharmacy's usual and customary, whichever is lower.network / U&C

DIR / price-concession exposurePart D only

Post-reform, all pharmacy price concessions are reflected at the point of sale. The 340B spread is no longer eroded months later by a retroactive clawback you never reserved for.POS-priced

Same point-of-sale treatment. The reform is NDC- and program-agnostic, so both streams reconcile on the same net-price rule.POS-priced

Where it breaksMost common defect

A patient who does not meet the 340B patient definition (no qualifying encounter with the covered entity) is tagged eligible anyway. Instant audit exposure.bad eligibility

A genuinely eligible dispense is left in the non-340B pile, so the pharmacy pays WAC and quietly forfeits the discount it was entitled to.missed capture

Operator note: the matrix is not documentation, it is the data model. Every field in the middle two columns should map to a stored attribute on the claim record. If your split lives in a spreadsheet a technician reconciles at month end, you do not have a split. You have a hope.

The claim-split, step by step

The fork happens once, at eligibility, and never gets re-litigated downstream.

Duplicate discounts are almost never a pricing error. They are a sequencing error, a claim that got its 340B identity assigned after it was already adjudicated. Here is the order that keeps it clean.

Step 01 / Intake

Capture the encounter, not just the prescription

Confirm the prescribing provider is employed by or contracted to the covered entity and that a qualifying visit exists. This is the HRSA patient definition test, and it is the whole ballgame.

Step 02 / Eligibility decision

Assign the 340B identity before adjudication

Check the covered entity's carve-in / carve-out posture against the HRSA Medicaid Exclusion File. The claim leaves this step tagged, and the tag is immutable.

Step 03A / Eligible route

340B stream

Replenish from the 340B account, apply SCC 20 on Medicaid FFS, and suppress the rebate request so the manufacturer discount is not double-claimed.

Step 03B / Non-eligible route

Non-340B stream

Replenish from WAC/GPO stock, adjudicate normally, and leave the rebate path open. No 340B indicator ever touches this claim.

Step 04 / Reconcile

Match each stream to its own net-revenue expectation

Eligible units reconcile spread against NADAC-based payment; both streams reconcile Part D net against the point-of-sale price. Variances are exceptions, not the norm.

Why the reconciliation changed

CMS moved the DIR fee from a retroactive surprise to a point-of-sale line item.

Before 2024, a Part D pharmacy booked revenue at adjudication and then lost an unpredictable slice of it months later as a direct and indirect remuneration clawback. For a 340B pharmacy that had already banked the spread, those clawbacks landed on margin that was supposed to fund the entity's mission. The reform reset the clock.

Through 2023

Retroactive DIR era

Pharmacy price concessions were assessed weeks to months after the sale. The point-of-sale price overstated true net, and 340B spread was eroded after the fact with no reliable reserve.

Effective January 1, 2024

CMS Part D DIR reform, point-of-sale rule

CMS redefined the negotiated price to reflect the lowest possible reimbursement, requiring all pharmacy price concessions to be applied at the point of sale. Retroactive pharmacy DIR clawbacks were effectively eliminated for Part D.

2024 and forward

Net revenue is knowable on day one

The point-of-sale price is now the net price. A 340B pharmacy can reconcile spread the same day it dispenses, and the eligible / non-eligible split is the only variable left that moves the number.

The reform did not raise or lower 340B economics on its own. It made them legible. What used to be a moving target is now a fixed figure, which is exactly why a clean claim-split finally pays off in a monthly close that actually ties.

What the reconciliation watches

Four control totals, illustrative, that a pharmacy-billing team reconciles every cycle.

These are the exception categories, not benchmarks. The bars show relative attention, not real client volumes. Your actual figures come from your own 340B split report and remittances.

Control 01

Eligibility integrity

Share of eligible tags backed by a documented qualifying encounter. Anything untied to an encounter is a duplicate-discount candidate.

Control 02

Exclusion File alignment

Carve-in claims that correctly carry SCC 20 and route through the entity's 340B BIN/PCN. Misalignment invites a state rebate clawback.

Control 03

NADAC pay-to-cost spread

Medicaid FFS remittance measured against NADAC ingredient cost plus the professional dispensing fee, split by stream.

Control 04

Part D point-of-sale net

Adjudicated net reconciled to the post-reform point-of-sale price. Post-2024, this should tie with almost no retroactive variance.

The guidelines this rests on

Real, named authorities. No interpretation you cannot trace back to a rule.

HRSA

340B Drug Pricing Program

Sets covered-entity eligibility, the ceiling-price calculation, the patient definition, and the statutory prohibition on duplicate discounts governed through the Medicaid Exclusion File.

CMS

Part D DIR Reform, point-of-sale price concessions

The CMS final rule redefining the negotiated price so all pharmacy price concessions apply at the point of sale, effective January 1, 2024, ending retroactive pharmacy DIR clawbacks in Part D.

CMS / State Medicaid

NADAC-based reimbursement

The National Average Drug Acquisition Cost survey that many state Medicaid fee-for-service programs use as the ingredient-cost basis, paired with a professional dispensing fee.

NCPDP / State manuals

Submission Clarification Code 20

The claim-level 340B indicator carried on Medicaid pharmacy claims so states suppress the manufacturer rebate on discounted units, as specified in individual state Medicaid pharmacy provider manuals.

Your split is either a data model or a liability.

ASP-RCM Solutions builds the eligible / non-eligible tag into the claim at adjudication, aligns it to your carve-in posture and the Medicaid Exclusion File, and reconciles both streams against NADAC pay and post-reform point-of-sale net. You get a monthly close that ties and an audit trail that holds. Let us pressure-test how your 340B pharmacy revenue reconciles today.

Talk through your 340B reconciliation →

ASP-RCM Solutions · Senior Partner · Frisco, Texas